tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Sanofi’s Pediatric Study on Unexplained Splenomegaly: Key Insights for Investors
PremiumCompany AnnouncementsSanofi’s Pediatric Study on Unexplained Splenomegaly: Key Insights for Investors
5d ago
Sanofi’s Promising Pipeline and Strategic Positioning Justify Buy Rating
Premium
Ratings
Sanofi’s Promising Pipeline and Strategic Positioning Justify Buy Rating
6d ago
Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval
Premium
The Fly
Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval
6d ago
Trump Trade: U.S. President signs new pharma order
PremiumThe FlyTrump Trade: U.S. President signs new pharma order
18d ago
Trump signs memorandum mandating pharma ads give more info on risks
Premium
The Fly
Trump signs memorandum mandating pharma ads give more info on risks
18d ago
Sanofi’s Amlitelimab: Buy Rating Amid Challenges and Opportunities in Atopic Dermatitis Market
Premium
Ratings
Sanofi’s Amlitelimab: Buy Rating Amid Challenges and Opportunities in Atopic Dermatitis Market
20d ago
Sanofi’s Promising Phase 3 Study on Frexalimab for Multiple Sclerosis
PremiumCompany AnnouncementsSanofi’s Promising Phase 3 Study on Frexalimab for Multiple Sclerosis
21d ago
Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
Premium
Company Announcements
Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
21d ago
Sanofi’s New Study on Amlitelimab Delivery: What Investors Need to Know
Premium
Company Announcements
Sanofi’s New Study on Amlitelimab Delivery: What Investors Need to Know
21d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100